期刊文献+

Sa抗原抗体免疫系统与类风湿关节炎 被引量:1

下载PDF
导出
出处 《山西医药杂志》 CAS 2004年第4期320-322,共3页 Shanxi Medical Journal
基金 山西省教育委员会科技开发资助项目 (研究类 990 33)
  • 相关文献

参考文献16

  • 1李小峰,张乃峥,李鸿斌,甘晓丹,唐福林,董怡,崔京涛,张帆.类风湿关节炎血清学早期诊断[J].中华风湿病学杂志,1999,3(4):208-211. 被引量:57
  • 2许尚栋,唐福林,史立,甘晓丹,史艳萍,陈琳洁,李家荣,董怡.抗Sa抗体在类风湿关节炎中的意义[J].中华内科杂志,1998,37(5):330-332. 被引量:20
  • 3Lopez-Longo FJ,Rodrfguez-Mahou M,Grau R,et al.Anti-Sa antibodies detected by indirect immunofluorescence in patients with rheumatoid arthritis.Arthritis Rheum,1997,40(Suppl):716.
  • 4Escalona M,Lopez-Longo FJ,Gonzolez CM,et al.Anti-Sa sera from patients with rheumatoid arthritis contain at least 2 different subpopulations of anti-Sa antibodies.J Rheumatol,2002,29(10):2053-2360.
  • 5Despres N,Boire G,Menard HA.The rheumatoid arthritis specific Sa autoantigen is present in high concentration in the target tissue (abstr).Arthritis Rheum,1992,35(Suppl):72.
  • 6Hueber W,Hassfeld W,Smolen JS,et al.Sensitivity and specificity of anti-Sa autoantibodies for rheumatoid arthritis.Rheumatology,1999,38:155-159.
  • 7Hayem G,Chazerain P,Combe B,et al.Anti-Sa antibody is an accurate diagnostic and prognostic marker in adult rheumatoid arthritis.J Rheumatol,1999,26(1):7-13.
  • 8Schellekens AM,Jong BAW,Hoogen FHJ,et al.Citrulline is an essential constituent of rheumatoid arthritis-specific epitopes.J Clin Invest,1998,101(1):273-281.
  • 9Despres N,Boire G,Lopez-Longo FJ,et al.The Sa system:a novel antigen-antibody system specific for rheumatoid arthritis.J Rheumatol,1994,21:1027-1033.
  • 10Zhou Z, Lapointe E, Richard C, et al. Autoantibodies to a 53 000 antigen of endothelial cells are highly specific for rheumatoid arthritis and related to anti-Sa.Arthritis Rheum,1999,42(Suppl):113.

二级参考文献2

  • 1张乃峥,中华内科杂志,1995年,34卷,79页
  • 2金冬雁(译),分子克隆实验指南(第2版),1994年,880页

共引文献72

同被引文献15

  • 1陈华,姚志建,唐福林.Sa抗原相关蛋白质的研究[J].中华医学杂志,2006,86(27):1896-1900. 被引量:7
  • 2邢艳丽,李静,耿美玉.细胞迁移中微丝微管的变化及其信号转导通路研究进展[J].现代生物医学进展,2007,7(6):919-922. 被引量:6
  • 3Clarke EJ, Allan V. Intermediate filaments: vimentin moves in[J]. Cu- rr Biol,2002,12(17):596-598.
  • 4Sabbah M, Emami S, Redeuilh G, et al. Molecular signature and thera- peutic perspective of the epithelial-to-mesenchymal transitions in epith- elial cancers[J]. Drug Resist Updat, 2008, 11(4-5): 123-151.
  • 5Satelli A, Li S. Vimentin in cancer and its potential as a molecular target for cancer therapy[J]. Cell Mol Life Sci, 2011,68(18):3033-3046.
  • 6Luime J J, Colin EM, Hazes JM, et al. Does anti-mutated citrullinated vimentin have additional value as a serological marker in the diagnost- ic and prognostic investigation of patients with rheumatoid arthritis? A systematic review[J]. Ann Rheum Dis, 2010, 69(2):337-344.
  • 7Malakoutikhah M, G6mara M J, G6mez-Puerta JA, et al. The use of ch- imeric vimentin citrullinated peptides for the diagnosis of rheumatoid arthritis[J]. J Med Chem, 2011, 54(21):7486-7492.
  • 8Vossenaar ER, Desprs N, Lapointe E, et al. Rheumatoid arthritis spe- cific anti-Sa antibodies target citrullinated vimentin [J]. Arthritis Res Ther, 2004, 6(2): 142-150.
  • 9Fuchs E, Weber K. Intermediate filaments: structure, dynamics, functi- on, and disease[J]. Annu Rev Biochem,1994, 63:345-382.
  • 10Franke WW, Grund C, Kuhn C, et al. Formation of cytoskeletal eleme- nts during mouse embryogenesis. IlL Primary mesenchymal cells and the first appearance ofvimentin filaments[J]. Differentiation,1982, 23: 43-59.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部